BP's interests in the Big Three
“The Company is engaged in discussions and negotiations
regarding the out-licensing
of its mid-stage, first-in-class clinical assets to global and/or specialty pharmaceutical companies who have expressed an interest in one or more assets in our pipeline.”
“The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review
“These recent data, taken in aggregate, are what various actively engaged pharmaceutical companies have desired from us for some time—and they are what triggered a newfound flurry of inbound partnership discussions at the San Francisco conferences,”
"To advance our pipeline in an expeditious manner, this year we placed an emphasis on partnering—actively engaging global and regional pharmaceutical companies interested in licensing our novel drug candidates. These efforts have led to highly productive, mature (late-phase, ongoing) discussions, with multiple pharmaceutical companies, which we hope will bear fruit in the coming year." - CEO Letter to Shareholders
"We had said that confidential disclosure agreements have been signed with several pharmas interested in our drug candidates; to some, they're interested in one compound. Others have requested information on a combination of Brilacidin and Kevetrin and Prurisol."
"To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets."
“Given the notable interest from global and specialty pharmaceutical companies that we have received following recent Brilacidin-OM data releases, we continue to carefully assess all of our potential alliance opportunities—toward cementing the best pathway forward,” said Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals.”
“Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.”
"We've actively engaged with multiple large pharmas, who have expressed an interest in Brilacidin inflammatory bowel disease. The pharma industry is quite interested in pursuing novel IBD therapies one of the more active therapeutic areas when it comes to dealmaking."
"We have entered into multiple non-disclosure agreements with large pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship."
"The Company is adhering to a value-building strategy born from discussions with larger pharmaceutical companies interested in Kevetrin, one of the world’s most advanced p53 drug candidates. Securing the right development partner for Kevetrin remains an important objective."
"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,"
Document - Getting Ready for a BioPharma Partnering Deal
A typical large pharmaceutical might see 500 to 1,000 opportunities in a given therapeutic area. Only 100 or so of those will go on to non-confidential meetings and only 50 or so of those will end up going to Confidential Disclosure Agreements (CDAs) and confidential meetings.
For a BP, only 5-10% of drugs ended up in a CDA and IPIX has ~20!
Unfortunately, getting a deal done can take a long time. After initial talks, getting a CDA can take a month or more. It might take another month for the other side to assemble appropriate team members and schedule team meetings.
It can then easily take another month for them to evaluate all the information and to decide that they will indeed go forward with the formal due diligence process. From the point when the other party has decided to go forward with term sheet negotiations, it can take another six to twelve months to get to a signature on a full agreement.
Key point: 6-12 months from negotiation to agreement.
Diligence and a Good Virtual Data Room
When a potential partner begins the due diligence process, they’re trying to get to know you and your asset in greater detail, and they’re attempting to verify what they’ve been told.
Give them access to your experts, provide overview presentations, and answer questions. In short, spend the time it takes to make sure they really understand it.
Virtual data room - check.